Media

Corgentech Appoints Dorian Rinella Vice President of Human Resources

SOUTH SAN FRANCISCO, Calif., March 1, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that Dorian Rinella has been appointed vice president of human resources. Ms. Rinella joins Corgentech from Kosan Biosciences in Hayward, CA, where she served as vice president, human resources and facilities.

At Corgentech, Ms. Rinella will function as our organizational strategist to attract, develop, and retain the best people. She will provide leadership to enhance our organizational effectiveness while further aligning human resources with our corporate strategy and goals, ensuring that the necessary infrastructure is in place. She will also serve as the key advisor to senior management on human resource issues and be responsible for benefits and compensation.

From 1991 to 2003, Ms. Rinella was employed by SUGEN, Inc., a Pharmacia Company that merged with Pfizer, serving in several management positions including senior vice president of operations. In that capacity, she had responsibility for human resources, information technology, finance and facilities, as well as employee-oriented integration programs relating to the acquisition of SUGEN.

Before joining SUGEN, Ms. Rinella held various positions in human resource management with Doric Development, a real estate development firm and Bio-Rad Laboratories, a manufacturer and distributor of life science research and clinical products.

"With a 20-year career that has included all aspects of human resource management within various types and sizes of corporate organizations, Dorian brings extensive experience to Corgentech that will be instrumental in helping us meet the needs of recruiting and retaining a top-notch, diverse workforce in order to achieve our goals," stated John McLaughlin, president and chief executive officer of Corgentech.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer. For more information on the company and its technology, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. These include without limitation statements related to our clinical trials, product candidates, and operations. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties detailed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

SOURCE Corgentech Inc.

Jennifer Cook Williams, Senior Director, Investor Relations of Corgentech Inc.,
+1-650-624-9600, or [email protected]

http://www.prnewswire.com

News Provided by COMTEX